Xebios Diagnostics Group GmbH

Xebios Diagnostics Group GmbH is a specialized company focused on the production and distribution of diagnostic culture media, primarily serving microbiological laboratories across various industries, including healthcare and environmental sectors. Founded in Düsseldorf, Germany, Xebios Diagnostics Group GmbH specializes in diagnostic culture media for laboratories. The company is not reported to have undergone significant pivots and does not mention subsidiaries. It was recently acquired by Solabia Group on March 6, 2026, with financial terms undisclosed.

The current CEO information is not provided. Xebios Diagnostics Group GmbH specializes in the production and distribution of diagnostic culture media and related services tailored for microbiological laboratories. Their core offerings include the Xebios myDCM services, which provide customized volumes of DCM (Diagnostic Culture Media) and supplements, designed to meet the specific requirements of laboratory preparators. The company’s culture media are recognized for their high sensitivity and selectivity in recovering Legionella spp.

from environmental water samples, with over 250 unique recipes that facilitate diverse applications in microbiological diagnostics. The clientele primarily consists of laboratories and research institutions within the healthcare, environmental, and food safety sectors, operating across Europe, Asia, and North America. Xebios also leverages modern technology through its Xebios-App, which optimizes inventory management, provides real-time product information, and supports quality control documentation. Xebios Diagnostics Group GmbH generates revenue primarily through the sale of its diagnostic media and services to commercial laboratories and research institutions.

Transactions typically occur on a B2B basis, where clients place orders for specific media products based on their laboratory needs and operational requirements. The company's flagship products include proprietary diagnostic culture media, sold in customizable volumes that allow clients to tailor their inventory to ongoing project demands. Pricing structures involve one-time purchases of media, with additional opportunities for clients to access subscription services for ongoing supply needs, ensuring consistent availability of essential materials. The Xebios model facilitates a direct relationship with its customers, enhancing service delivery and client satisfaction through personalized support and inventory management solutions.

Xebios Diagnostics Group GmbH's growth strategy focuses on broadening its product capabilities, as evidenced by the acquisition by Solabia Group. This acquisition aims to accelerate the next phase of growth for Xebios. Details about upcoming products and specific release dates have not been disclosed. The company is expected to leverage this acquisition to expand its market reach, targeting new geographic regions in the future.

With the acquisition completed in March 2026, Xebios is poised to enhance its service offerings and explore additional market opportunities.